Skip to main content
KAPA logo

Kairos Pharma, Ltd.

KAPANYSEAMERICANHealthcareBiotechnology

$0.67Today:- (-)1Y −42.19%

As of Oct 15, 2026 close

Market cap
$14.36M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.43$3.51
Volume (live)
-
Avg. volume (3M)
673.05K

Kairos Pharma (KAPA) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Kairos Pharma used $3.44M of cash in operating activities. Free cash flow was −$3.44M.

Kairos Pharma Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kairos Pharma, Ltd. (KAPA) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-5.45-2.60-1.81-1.05-2.15-1.05
Depreciation & Amortization0.160.160.160.160.100.00
Stock Based Compensation0.480.220.910.000.300.80
Change in Working Capital-0.81-1.980.760.131.190.21
Change in Accounts Payable-0.790.400.000.130.000.21
Change in Other Working Capital-0.01-2.390.760.411.190.21
Other Operating Activities2.170.250.060.410.140.00
Net Cash from Operating Activities-3.44-3.960.08-0.35-0.41-0.04
Investing Activities
Capital Expenditures0.000.000.000.000.000.00
Acquisitions0.000.000.000.00-0.110.00
Net Cash from Investing Activities0.000.000.000.00-0.110.00
Financing Activities
Debt Repayment0.00-0.140.00-0.030.33-0.01
Common Stock Issued6.665.52-0.43-0.060.250.00
Other Financing Activities3.06-0.390.00-0.180.00-0.01
Net Cash from Financing Activities6.665.13-0.430.720.580.04
Summary
Net Change in Cash3.221.18-0.340.360.060.00
Cash at Beginning of Period1.270.090.440.070.010.02
Cash at End of Period4.491.270.090.440.070.01
Free Cash Flow-3.44-3.960.08-0.35-0.41-0.04
Supplemental Disclosures
Interest Paid-0.00----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Kairos Pharma Cash Flow

What is Kairos Pharma's free cash flow?

Kairos Pharma had negative free cash flow of $3.44M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Kairos Pharma pay dividends or buy back shares?

Kairos Pharma's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition